Balance Sheet

Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Rhythm Pharmaceuticals (RYTM) Change in Intangibles (2023 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Intangibles for 2 consecutive years, with $500000.0 as the latest value for Q3 2024.

Quarterly Change in Intangibles rose 83.82% to $500000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $500000.0 through Dec 2025, down 98.77% year-over-year, with the annual reading at $40.0 million for FY2025, 1.23% down from the prior year.
Change in Intangibles for Q3 2024 was $500000.0 at Rhythm Pharmaceuticals, down from $40.0 million in the prior quarter.
The five-year high for Change in Intangibles was $40.0 million in Q1 2024, with the low at $272000.0 in Q3 2023.